Project Number ADDF-48 Agency/Funding Organization Alzheimer's Drug Discovery Foundation Funding Year 2021 View Full Project Details for Testing low-dose efavirenz treatment for Alzheimer’s disease: a phase 1b dosing, target-engagement and exploratory biomarker study. Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials) r. Multi-target Researcher and Organization Principal Investigator SCHELTENS, PHILIP Principal Investigator First Name PHILIP Principal Investigator Last Name SCHELTENS Awardee Organization Vrije Universiteit Amsterdam Contact PI Country The Netherlands Project Detail Funding Opportunity Announcement ADDF-Clinical Trial Program FY Overall Cost $855,541 Funding Organization Agency/Funding Organization Alzheimer's Drug Discovery Foundation Funding Organization Country United States Program Official ADDF Grants Management